Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
0.9950
+0.0685 (7.39%)
At close: Nov 6, 2026, 4:00 PM EST
1.000
+0.005 (0.50%)
After-hours: Nov 6, 2026, 7:30 PM EST
Cardiol Therapeutics Employees
Cardiol Therapeutics had 18 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
18
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,333,133
Market Cap
116.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 18 | 0 | - |
| Dec 31, 2024 | 18 | - | - |
| Dec 31, 2018 | 6 | - | - |
| Sep 30, 2018 | 8 | - | - |
| Jun 30, 2018 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Organigram Global | 1,120 |
| Organogenesis Holdings | 854 |
| Glass House Brands | 426 |
| Zhengye Biotechnology Holding | 269 |
| Anika Therapeutics | 235 |
| Akebia Therapeutics | 194 |
| ADC Therapeutics | 193 |
| Cumberland Pharmaceuticals | 88 |
CRDL News
- 5 days ago - Cardiol Therapeutics announces $75M ATM equity offering program - TheFly
- 5 days ago - Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC - PRNewsWire
- 6 weeks ago - Cardiol Therapeutics Slides: Corporate presentation - Filings
- 6 weeks ago - Cardiol Therapeutics achieves enrollment target for Phase III MAVERIC trial - TheFly
- 6 weeks ago - Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy - PRNewsWire
- 7 weeks ago - Cardiol Therapeutics Registration statement: Registration filing - Filings
- 7 weeks ago - Cardiol Therapeutics receives over $7M in proceeds from warrant exercise - TheFly
- 7 weeks ago - Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds - PRNewsWire